Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Yago Nieto et al.|Nature Medicine|2024Cited by 452
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|Cancer Cell|2022Cited by 338
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cellsMay Daher, Katayoun Rezvani|Blood|2020Cited by 284
Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor ImmunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|SSRN Electronic Journal|2021Cited by 24